This article is more than 5 years old. Information may no longer be current.

FDA approves phase 3 study protocol for Evosyal

Alphaeon Corporation announced that the FDA has approved the protocol for its phase 3 clinical study of Evosyal for the treatment of glabella lines.

The company acquired exclusive U.S. and certain international distribution rights for Evosyal (botulinum toxin Type A neuromodulator) through its acquisition of Evolus. During the past 12 months, Alphaeon submitted an investigational new drug application for the botulinum toxin Type A neuromodulator and completed enrollment for its phase 2 study, according to a company press release.

Enrollment for the phase 3 study began this month, according to the release.

Reference: www.alphaeon.com.